#United States #Houston #Plant-Based #Stramsen Biotech #GEM Global

Stramsen Biotech Inc. Secures $25 Million Funding Commitment

Stramsen Biotech Inc., a frontrunner in the plant-based biopharmaceutical industry, has recently entered into a binding agreement with GEM Global Yield LLC SCS ("GEM"), marking a significant milestone in its growth journey. This collaboration will see Stramsen receiving a $25 million share subscription facility, which will be utilized over a 36-month period post the public listing of Stramsen's stock.

A Boost for Growth and Clinical Development

The funds from GEM will be strategically allocated to accelerate Stramsen's growth trajectory. This investment is not just a financial boost but also signals the trust GEM has in Stramsen's vision of offering nature-based, sustainable health solutions that minimize side effects for patients around the globe.

Scott Villwock, the President and CEO of Stramsen Biotech, emphasized the significance of this commitment, stating, "This commitment from GEM validates Stramsen Biotech's vision of providing nature-based, sustainable, and affordable health solutions with minimal side effects to patients worldwide."

With full control over the timing and the maximum amount of drawdowns from the facility, Stramsen has the flexibility to manage its capital needs strategically, without a mandated minimum drawdown requirement.

Key Growth Objectives

The $25 million infusion will primarily facilitate the following growth strategies:
1. Global Expansion Initiatives: Stramsen is set to enhance its presence globally, aspiring to establish itself as a leader within the plant-based biopharmaceutical landscape.
2. Initial Public Offering Preparation: With aspirations for a public listing, Stramsen aims to utilize this funding towards preparing a prospectus for submission, which is pivotal for their IPO plans.
3. R&D Investment: The company will focus on its research and development initiatives, aiming to advance 33 innovative drug candidates that leverage their proprietary knowledge of medicinal plants.
4. FDA Applications: Stramsen intends to initiate multiple Investigational New Drug (IND) submissions to the FDA, propelling its pipeline toward clinical trials.
5. Expert Team Expansion: The company aims to establish a Scientific Advisory Board while expanding its cadre of seasoned scientists, thereby reinforcing its expertise in the biopharmaceutical field.

About Stramsen Biotech Inc.

Stramsen Biotech is pioneering the development of plant-based medicines targeting both infectious and non-infectious diseases. With access to an extensive database of medicinal plants and a robust pipeline of drug candidates, Stramsen is positioned at the forefront of biopharmaceutical innovation. Their commitment to leveraging natural alternatives reflects a growing trend towards sustainability in healthcare, aiming to revolutionize how diseases are treated globally.

To learn more about Stramsen Biotech Inc., you can visit www.stramsenbiotech.com.

About GEM

GEM Global Emerging Markets is a renowned alternative investment group managing a diverse array of investment vehicles, with a portfolio exceeding $3.4 billion and over 600 transactions across 72 countries. GEM specializes in private investments across various asset classes, providing their partners exposure to a wide spectrum of investment opportunities. Their strategic investments aim to drive growth for emerging companies, positioning them favorably within competitive landscapes.

For further inquiries or to learn more about Stramsen Biotech's latest developments, contact Scott Villwock at 713-955-5115 or via email at [email protected].